Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification

Kamiyama, Toshiya; Orimo, Tatsuya; Wakayama, Kenji; Shimada, Shingo; Nagatsu, Akihisa; Yokoo, Hideki; Kamachi, Hirofumi; Yamashita, Kenichiro; Shimamura, Tsuyoshi; Taketomi, Akinobu

doi:10.1186/s12957-017-1229-x

World Journal of Surgical Oncology

Table 1 Univariate analysis of variables predictive (clinical and tumor associated factors) for stage B HCC patient survival and recurrence

From: Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification

Variables			p value	p value
Variables		n	Survival	Recurrence
Sex	Male	253	0.9880	0.1503
Sex	Female	44
Age	<60	117	0.9306	0.4414
Age	≥60	180
HBV	Negative	191	0.0516	0.2386
HBV	Positive	105
HCV	Negative	210	0.7523	0.2126
HCV	Positive	87
Albumin (g/dl)	<4	139	0.0006	0.0439
Albumin (g/dl)	≥4	158
Total bilirubin (mg/dl)	<0.8	160	0.2827	0.4807
Total bilirubin (mg/dl)	≥0.8	137
ICGR15 (%)	<15	178	0.3471	0.1136
ICGR15 (%)	≥15	119
Tumor number	1	145	<0.0001 ^*1	<0.0001 ^*2
	2or3	100
	≥4	52
Tumor size (cm)	≤3	8	0.9998	0.7932
	3–5	54
	≥5	235
Anatomical resection	Yes	241	0.0182	0.2306
Anatomical resection	No	56
Blood loss (ml)	<1100	239	0.0027	0.1937
Blood loss (ml)	≥1100	58
AFP (ng/ml)	≤200	201	0.0028 ^*3	0.1276
	200–1000	26
	>1000	70
PIVKA-II (mAU/ml)	≤100	82	0.0354 ^*4	0.0048 ^*5
	100–1000	75
	>1000	139
AP-factor (AFP*PIVKA-II)	AP1	65	<0.0001 ^*6	0.0009 ^*7
	AP2	99
	AP3	133
Differentiation	Well	19	0.2092	0.1655
	Moderate	160
	Poor	115
	Unknown	19
Microscopic portal vein invasion	vp0	205	0.0003 ^*8	0.0103 ^*9
	vp1	62
	vp2	28
	Unknown	1
Microscopic hepatic vein invasion	vv0	271	0.01463 ^*10	0.0262^*11
	vv1	25
	Unknown	1
Non-cancerous liver	Cirrhosis	67	0.1328	0.1772
Non-cancerous liver	Non-cirrhosis	230

HbsAg, hepatitis B virus s antigen; HCV, anti-hepatitis C virus antibody; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonism factor II; ICGR15, indocyanine green retention rate at 15 min; AP-factor, a product of the serum levels of AFP and PIVKA-II. HCC patients were classified into three groups: AP1 (AFP < 200 ng/ml and PIVKA-II < 100 mAU/ml), AP2 (AFP × PIVKA-II < 10⁵), and AP3 (AFP × PIVKA-II ≥ 10⁵)
vp0: no tumor thrombus in the portal vein
vp1: tumor thrombus distal to the second branches of the portal vein
vp2: tumor thrombus in the second branches of the portal vein
vv0: no tumor thrombus in the hepatic vein
vv1: tumor thrombus in a branch of the hepatic vein
When the subgroups were more than three, p-value in Table 1 was showed a significant difference as a group. P-value between the subgroups was showed with asterisk
^*1: tumor number 1 vs ≥4 (p < 0.0001), tumor number 2or3 vs ≥4 (p = 0.0003)
^*2: tumor number 1 vs 2or3 (p = 0.0047), tumor number 1 vs ≥4 (p < 0.0001), tumor number 2or3 vs ≥4 (p = 0.0122)
^*3: AFP ≤ 200 vs 200–1000 (p = 0.0072), ≤200 vs >1000 (p = 0.0009)
^*4: PIVKA-II ≤100 vs >1000 (p = 0.0043)
^*5: PIVKA-II ≤100 vs 100–1000 (p = 0.0009), ≤100 vs >1000 (p = 0.0224)
^*6: AP-1 vs Ap-3 (p = 0.0001), AP-2 vs Ap-3 (p < 0.0001)
^*7: AP-1 vs Ap-3 (p = 0.0012), AP-2 vs Ap-3 (p = 0.0074)
^*8: vp0 vs vp1 (p = 0.0005), vp0 vs vp2 (p < 0.0001)
^*9: vp0 vs vp2 (p = 0.0024)
^*10: vv0 vs vv1 (p = 0.0123)
^*11: vv0 vs vv1 (p = 0.0181)

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com